Tag: Xanomeline

Approved by the FDA in September 2024, the Cobenfy drug represents the first new mechanism of action for schizophrenia treatment in decades. This innovative oral medication provides an alternative for adults with schizophrenia who may not respond to or tolerate traditional antipsychotic therapies.

In clinical trials, approximately 19% of patients taking xanomeline/trospium (Cobenfy) reported nausea as a common side effect. Understanding what are the side effects of xanomeline, which is combined with trospium to mitigate some adverse reactions, is crucial for anyone considering or currently on this novel antipsychotic medication.

In September 2024, the FDA approved xanomeline-trospium (Cobenfy) for the treatment of schizophrenia, representing the first new class of antipsychotic medication to market in decades that does not primarily target dopamine receptors. Understanding **how does xanomeline affect the brain?** requires exploring its innovative mechanism centered on the brain's cholinergic system, a fundamental pathway for cognition and behavior.

Worldwide, over 20 million people live with schizophrenia, yet up to 30% of patients do not respond well to traditional treatments [1.2.4, 1.6.2]. So, is xanomeline an antipsychotic? Yes, it represents the first in a new class of antipsychotics with a novel mechanism of action [1.2.1, 1.3.3].

In September 2024, the FDA approved Cobenfy, representing the first new class of medicine for schizophrenia in decades. This oral prescription medication is not a single drug but a combination product, which is why the question of what is the generic name for COBENFY is best answered by listing its two active components.

According to clinical trials, Cobenfy significantly reduced the severity of schizophrenia symptoms in adults within five weeks. **How does Cobenfy make you feel?** The medication can alleviate positive symptoms like hallucinations and delusions, while also addressing negative symptoms such as emotional flatness or lack of motivation.

In September 2024, the FDA approved the first new class of antipsychotic medications in decades, containing the active muscarinic agonist **xanomeline**. This oral medication, marketed as Cobenfy, represents a significant paradigm shift by targeting cholinergic receptors to treat schizophrenia in adults.